Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

The idea of creating a gray zone in the payer message is to take the onus off of having to heavily discount for equal access ...

The growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such ...

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years ...

With this is mind, Abbott announced a new program that combines one of the most popular sports in the world with education ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement ...

The aura6000 system showed a 65% responder rate at 12 months in patients with obstructive sleep apnea, defined as achieving ...

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services ...

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, ...

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...